Chemomab Therapeutics jumps as liver fibrosis drug meets goals in mid-stage study

Chemomab Therapeutics

03/01/2023 13:05

** Shares  CMMB.O  of Israel-based drug developer Chemomab
Therapeutics Ltd up 43.1% at $4.58 premarket
    ** Company says investigational drug meets goals in
mid-stage study in non-alcoholic steatohepatitis (NASH) patients
    ** Drug continues to appear safe and was well-tolerated when
administered under the skin - CMMB
    ** Patients administered with the drug showed greater
improvements than the placebo group for liver fibrosis, or
scarring in the liver tissues, company says
    ** NASH is a type of fatty liver disease, characterized by
inflammation of liver due to fat accumulation 
    ** Last year, company's shares down 53.6% YTD
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))